Biotech Showcase™ 2017: The financial continuum and value creation

January 18, 2017
Biotech financial markets were buffeted by the winds of macro-economic events in 2016 ranging from the Brexit vote to the unprecedented presidential election in the US. In this new year we will take stock of what we might expect for biotech investment in 2017. Venture capitalists, corporate VCs, crossover investors and I-bankers share their outlooks for the coming year.
Previous Video
Biotech Showcase™ 2017: What's ahead with the new Trump administration?
Biotech Showcase™ 2017: What's ahead with the new Trump administration?

It’s no secret that the life sciences industry has had some challenging moments with lawmakers in recent ye...

Next Video
BIO-Europe® 2016: InflaRX CEO highlights pipeline goals
BIO-Europe® 2016: InflaRX CEO highlights pipeline goals

Niels Riedemann, founder and CEO of InflaRX, speaks to Lucie Ellis, senior writer at Scrip, about the compa...